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CD8 T cells are necessary for controlling tumors induced by mouse polyoma virus (PyV), but the effector mechanism(s) responsible have not
been determined. We examined the PyV tumorigenicity in C57BL/6 mice mutated in Fas or carrying targeted disruptions in the perforin gene or in
both TNF receptor type I and type II genes. Surprisingly, none of these mice developed tumors. Perforin/Fas double-deficient radiation bone
marrow chimeric mice were also resistant to PyV-induced tumors. Anti-PyV CD8 T cells in perforin-deficient mice were found not to differ from
wild type mice with respect to phenotype, capacity to produce cytokines or maintenance of memory T cells, indicating that perforin does not
modulate the PyV-specific CD8 T cell response. In addition, virus was cleared and persisted to similar extents in wild type and perforin-deficient
mice. In summary, perforin/granzyme exocytosis is not an essential effector pathway for protection against PyV infection or tumorigenesis.
© 2006 Elsevier Inc. All rights reserved.Keywords: Polyoma virus; CD8 T cell; Perforin; Fas; TNF; Tumor; PathogenesisIntroduction
Polyoma virus (PyV) is a prevalent mouse pathogen that is
capable of potent oncogenicity when inoculated into immuno-
compromised adult mice or newborn mice of certain strains
(Law et al., 1967; Dawe et al., 1987). Early studies using
thymectomized or congenitally athymic mice established that T
cells mediate resistance against PyV-induced tumors (Law,
1965; Allison et al., 1974). Class I MHC-restricted virus-
specific CD8 T cells have been implicated as anti-polyoma-
tumor immune effectors (Greene et al., 1982; Ljunggren et al.,
1994). In addition, susceptibility to PyV tumorigenesis results
from a hole in the PyV-specific CD8 T cell repertoire created by
an endogenous superantigen (Lukacher et al., 1995; Lukacher
and Wilson, 1998). Finally, Drake et al. demonstrated that
β2m
−/− mice are highly susceptible to PyV-induced tumors,
providing the first direct evidence that class I MHC-restricted T
cells prevent tumors resulting from PyV infection (Drake and
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doi:10.1016/j.virol.2006.08.044The long-term persistence of PyV DNA in multiple organs
of adult-inoculated mice, together with evidence that priming
of naive virus-specific CD8 T cells occurs during persistent
infection, indicates that PyV-specific CD8 T cells repetitively
encounter viral antigen during the persistent phase of PyV
infection (Drake and Lukacher, 1998; Kemball et al., 2005;
Vezys et al., 2006). Antiviral memory-stage CD8 T cells
display extremely efficient in vivo cytotoxicity against peptide
epitope-pulsed spleen cells (Barber et al., 2003; Byers et al.,
2003). These studies implicated the perforin/granzyme exocy-
tosis pathway as the dominant mechanism for clearance of
antigen-pulsed spleen cells in vivo (Byers et al., 2003). In the
context of a persistent PyV infection, this mechanism of CD8
T cell-mediated cytotoxicity was thus considered essential for
limiting viral replication and, in the case of non-productive
viral replication, tumor formation.
The dependence on perforin in host resistance to viral
infection, however, varies with the pathogen (Mullbacher et
al., 2004). Perforin-mediated cytotoxicity is essential for
control of infection by LCMV, ectromelia virus, Ebola virus
or Thelier's virus (Kagi et al., 1994; Mullbacher et al., 1999;
Gupta et al., 2005; Rossi et al., 1998; Walsh et al., 1994),
while it is not necessary for controlling other viral infections
(Franco et al., 1997; Kagi et al., 1995; Topham et al., 1997).
Table 1
PyV tumorigenesis in mice deficient in perforin, Fas or TNF receptors
Mouse strain Age of inoculation Tumor incidence a
B6.β2m
−/− Adult 7/10
B6.PKO Adult 0/10
B6.lpr Adult 0/12
B6.TNFR−/− Adult 0/12
C57BL/6 Adult 0/12
B6.PKO Newborn 0/11
C57BL/6 Newborn 0/10
a Adult-inoculated mice were monitored for 6 months; if free of palpable
tumors, mice were necropsied for evidence of overt visceral tumors. Tumor-
bearing B6.β2m
−/− mice were necropsied at 9–13 weeks, when tumors
(predominantly of the salivary gland) attained a size necessitating euthanasia.
Newborn mice were inoculated by PyV within 12 h of birth and were monitored
for 4 months for development of tumors then necropsied.
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noncytopathic (e.g., hepatitis B virus, LCMV) does not predict
a requirement for perforin in antiviral immunity (Mullbacher
et al., 2004), and the extent of viral control by perforin-
deficient mice can vary even between infections by closely
related viral infections (Mullbacher, 2003).
Immune mechanisms that control viral replication during
persistent viral infections may also vary between acute and
persistent phases of infection. For example, during murine
cytomegalovirus (MCMV) infection, viral replication in the
salivary glands is dependent on perforin during acute
infection while control of persistent MCMV infection is
independent of perforin-mediated exocytosis (Riera et al.,
2000). Alternatively, control of γHV68 infection is not
affected by loss of perforin during the acute immune response
(Topham et al., 2001; Usherwood et al., 1997), but perforin-
deficient mice have increased numbers of latently infected
cells compared to wild type mice (Tibbetts et al., 2002).
In this study, we investigated the contribution of perforin/
granzyme exocytosis to the control of viral replication during
acute and persistent phases of PyV infection. In particular,
we sought to determine whether perforin-mediated cytotoxi-
city represented the dominant pathway engaged by CD8 T
cells to prevent PyV tumorigenesis. Unexpectedly, we found
that perforin-deficient mice efficiently limited acute PyV
infection and retained resistance to PyV-induced tumors. In
addition, PyV-specific CD8 T cell responses in these mice
were indistinguishable from those of wild type mice. Thus,
we found no evidence for an immunomodulatory role for
perforin in the CD8 T cell response to PyV infection or for
perforin/granzyme exocytosis as an essential antiviral or
antitumor effector mechanism against this mouse pathogen.
Results
Analyses of PyV tumor induction in perforin, Fas and TNF
receptor-deficient mice
To identify candidate cytotoxic effector mechanisms that
could confer protection from PyV-induced tumors, adult
C57BL/6 mice mutated in Fas (lpr) or carrying targeted
disruptions in the perforin gene (PKO) or in both TNF
receptor type I and type II genes (TNFR−/−) were inoculated
subcutaneously by PyV and monitored for tumors. MHC
class I-deficient C57BL/6.β2m
−/− mice and wild type
C57BL/6 mice served as controls for PyV-induced tumor
susceptibility and resistance, respectively. Seven of ten
C57BL/6.β2m
−/− mice developed tumors within 3 months
of PyV infection (Table 1). Tumors in these mice almost
exclusively arose in salivary and mammary glands, which
are among the most frequent types of PyV-induced tumors,
particularly in immunocompromised adult mice (Berebbi et
al., 1988; Drake and Lukacher, 1998). During the same 3-
month period, the 3 overtly tumor-free C57BL/6.β2m
−/−
mice developed hind-limb paralysis, presumably caused by a
vertebral bone tumor (Wirth et al., 1992). None of the Fas-
defective, TNFRKO or PKO mice developed tumors duringthe 6-month monitoring period. Because high susceptibility
to PyV-induced tumors is realized only in particular inbred
strains of immunocompetent mice when inoculated at birth,
we also monitored the incidence of PyV-induced tumor
growth in neonatally infected PKO and wild type C57BL/6
mice. Neither newborn-infected PKO nor wild type mice
developed tumors (Table 1). Taken together, these data
indicate that the FasL/Fas, perforin/granzyme and TNFR-
mediated effector pathways are individually dispensable in
controlling PyV tumorigenesis.
Because PKO mice retained resistance to PyV-induced
tumors, we next asked whether PKO and wild type mice
differed in efficiency of viral clearance. Viral plaque assays
performed on splenic homogenates showed similar peak
titers and rates of clearance of infectious virus by PKO and
wild type mice during acute infection (Fig. 1A). Real-time
PCR for PyV DNA showed that there were no significant
differences between wild type and PKO mice in acute viral
load in spleen, lung or liver (Fig. 1B). Interestingly,
compared to persistently infected wild type mice, persistently
infected PKO mice had comparable viral loads in the spleen
but harbored significantly higher amounts of viral DNA in
lung and heart (Fig. 1C). We recently reported that in vivo
blockade of CD28 and CD40 ligand costimulatory pathways
is similarly associated with interorgan variability in PyV load
(Kemball et al., 2006); however, the mechanisms regulating
organ-specific immune control of persistent PyV infection
remain to be defined.
PyV-specific CD8 T cell response in PKO mice
PKO mice infected with either LCMV or Listeria display
massive expansion of activated Ag-specific CD8 T cells
(Kagi et al., 1999; Matloubian et al., 1999; Badovinac et al.,
2000), implicating a downmodulatory role for perforin in
CD8 T cell responses during acute infection. In PyV-infected
PKO mice, however, total numbers of splenic CD8 T cells
specific for the dominant Db-restricted LT359 epitope were
similar to that seen in wild type C57BL/6 mice during the
peak of the acute response, the contraction phase and the
Fig. 1. PyV clearance in wild type and PKO mice. (A) Spleens from wild type
(C57BL/6) and PKO mice at the indicated days postinfection were harvested,
homogenized and titered for PyV by plaque assay. Each value represents the
mean±SEM PFU/mg from 3 individual mice and is representative of 2
experiments. *, below detection limit of 1 PFU/mg. (B and C) Levels of PyV
DNA in the indicated organs of C57BL/6 or PKO mice during acute (B, day
8 postinfection) or persistent (C, >40 days postinfection) phase of infection were
quantitated by Taqman real-time PCR. Student's t-test values between C57BL/6
and PKO: acute spleen p=0.29, acute lung p=0.30, acute heart p=0.62;
persistent spleen p=0.31, persistent lung p<0.001, persistent heart p=0.03.
Mean±SEM values for 3 mice per group are shown and data are representative
of 2 experiments.
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numbers of PyV-specific CD8 T cells in the liver and
lungs of PKO and wild type mice were not substantially
different (data not shown). No overt phenotypic differences
distinguished PyV-specific CD8 T cells in PKO and wild
type mice. Nearly identical frequencies of LT359-specific
CD8 T cells in PKO and wild type mice expressed the IL-7
receptor α chain (CD127), the IL-2/IL-15 receptor β chain
and the TNF receptor family member CD27 during the
course of PyV infection (Fig. 2B). PKO and wild type mice
had a similar anti-PyV CD8 T cell hierarchy for the
dominant LT359 and subdominant MT246 and LT638
epitopes (Kemball et al., 2005) (data not shown).
Production of granzyme B, a serine protease that resides in
cytotoxic granules with perforin also did not differ between wild
type and PKO mice during the acute PyV immune response
(Fig. 3A). Additionally, frequencies of LT359 peptide-stimu-
lated CD8 T cells expressing surface CD107a, a lysosomal
membrane protein expressed on the surface of degranulating T
cells (Betts et al., 2003), were similar throughout the immune
response in both mice (data not shown). LT359 peptide
stimulation elicited similar frequencies of CD8 T cells
producing the antiviral cytokines IFN-γ and TNF-α in both
wild type and PKO mice (Fig. 3B). These phenotypic and
functional data suggest that PyV-specific CD8 T cells in PKO
mice complete the same program of differentiation as those in
infected wild type mice.
In vivo antigen-specific cytotoxicity in PKO mice
Lack of tumor formation in mice deficient in components
of the Fas/FasL and TNF/TNFR pathways (Table 1) could
indicate that absence of an individual CTL effector pathway
may not be sufficient to render mice susceptible to PyV-
induced tumors. In support of the potential requirement for
multiple cytotoxic effector modalities in antiviral clearance,
Topham and colleagues showed that deficiency in both
perforin and Fas was required to negate control of pulmonary
γHV68 replication (Topham et al., 2001). Although acutely
PyV-infected Fas-deficient mice killed LT359 peptide-pulsed
targets in vivo as efficiently as wild type mice, acutely
infected PKO mice retained substantial in vivo LT359-
specific cytotoxicity, albeit at much lower levels than in
C57BL/6 mice (Byers et al., 2003). This finding raised the
possibility for redundancy in these two CTL effector
pathways. To test this, we found that LT359 peptide-pulsed
lpr splenic target cells were eliminated with markedly
reduced efficiency compared to identically treated wild type
targets in PKO mice (Fig. 4A). This result supports the
likelihood that PyV-specific CD8 T cells engage both
perforin/granzyme exocytosis and Fas/FasL effector pathways
in infected mice.
In wild type mice, antiviral memory CD8 T cells rapidly
mobilize potent in vivo cytotoxic function to nearly the same
extent as antiviral CD8 T cells from acutely infected mice
(Byers et al., 2003). Acutely infected PKO mice eliminate
approximately 30% of LT359 peptide-pulsed targets during a
488 A.M. Byers et al. / Virology 358 (2007) 485–4924-hour in vivo CTL assay (Byers et al., 2003). However,
over the same time period, virtually none of the peptide-
pulsed targets is eliminated in persistently infected PKOmice (Fig. 4B). These data indicate that alternative effector
pathways do not compensate for the absence of perforin
during the persistent phase of PyV infection.
Analysis of PyV tumorigenesis in the absence of both Fas and
perforin
To more definitively test the in vivo effects of eliminating
both perforin- and Fas/FasL-mediated effector pathways in
PyV-infected mice, we created radiation bone marrow
chimeras doubly deficient in Fas and perforin, as previously
described (Topham et al., 2001). Lethally irradiated wild type
C57BL/6 or Fas-deficient B6.lpr mice were reconstituted with
bone marrow cells from PKO mice, infected by PyV and
monitored for virus levels and tumor formation. Reconstitution
of wild type mice with PKO bone marrow cells served as a
control to determine whether perforin-deficient radiation bone
marrow chimeras recapitulate the effective antiviral immune
response seen in gene targeted PKO mice. PCR analysis
confirmed that these reconstituted mice contained the same
mutated pfp gene as the PKO mice (data not shown). The use
of this radiation bone marrow chimera approach circumvents
the spontaneous autoimmunity and early mortality seen in
perforin/FasL double-deficient mice (Spielman et al., 1998).
Six months after PyV infection, none of the PKO:lpr chimeric
mice developed overt tumors. PKO:C57BL/6 chimeric mice
could not be monitored for long-term tumor growth because all
of these chimeric mice died between 8 and 16 weeks after PyV
infection. None of these mice showed signs of overt tumor
growth, and no gross tumors were seen on necropsic
examinations of several agonal mice (data not shown). In
addition, these mice showed marked morbidity (i.e., runting,
hunched posture and dyspnea), symptoms not seen in
unirradiated PKO mice. Three of nine PyV-infected PKO:lpr
chimeras also showed signs of morbidity between 20 and
32 weeks postinfection, and necropsies of these mice showed
no overt tumors (data not shown). The absence of PyV-induced
tumors in the remaining PKO:lpr chimeras indicates that non-
perforin/Fas-mediated effector mechanisms are responsible for
immunosurveillance for PyV-induced tumors. It is interesting
to note that Topham et al. described similar deleterious
outcomes in chimeric perforin-deficient, Fas-sufficient mice
inoculated intranasally with γHV68 and raised the possibility
that irradiation may increase expression levels of Fas in the
lung and consequently increased levels of Fas/FasL-mediated
lysis (Topham et al., 2001). Because PyV remains a silent
infection in unirradiated PKO mice, the higher incidence of
lethality in the PKO:C57BL/6 than the PKO:lpr chimeric miceFig. 2. Visualization of the PyV-specific CD8 T cell response in PKO mice. (A)
Spleen cells from PKO (■) or C57BL/6 (♦) mice at the indicated day after
infection were stained ex vivo with anti-CD8α and Db LT359 tetramers and
analyzed by flow cytometry. (B) Spleen cells from PKO (■) or C57BL/6 (♦)
mice at the indicated day after infection were stained ex vivo with anti-CD8α,
Db LT359 tetramers and anti-CD127, anti-CD122 or anti-CD27 and analyzed by
flow cytometry. Data are representative of 3 experiments with 3 mice per
experiment.
Fig. 3. PyV-specific CD8 T cells in PKO and wild type mice are functionally
similar. (A) Spleen cells from C57BL/6 or PKOmice at day 8 postinfection were
stained ex vivo with anti-CD8α and Db LT359 tetramers and intracellularly for
anti-granzyme B and analyzed by flow cytometry. Plots are gated on CD8 T
cells, and numbers indicate the percentage of cells in the indicated quadrant.
Data are representative of 3 experiments with 3 mice per experiment. (B) Spleen
cells from C57BL/6 and PKO mice at day 8 postinfection were stimulated with
or without 10 μm LT359 peptide for 5 h in the presence of BFA then surface-
stained with anti-CD8α and intracellularly stained for IFN-γ or TNF-α and
analyzed by flow cytometry. Plots are gated on live lymphocytes. Axes of the
plots are log of fluorescent intensity. Data are representative of 2–3 experiments
with 3 mice per experiment.
Fig. 4. Dependence of PyV-specific in vivo CTL activity on perforin and Fas.
(A) LT359 peptide-pulsed and unpulsed naive C57BL/6, lpr or TNFR−/− spleen
cells were injected into C57BL/6 mice 7 days after PyV infection. Peptide-
pulsed and unpulsed naive C57BL/6 spleen cells were injected into PKO mice
7 days postinfection. Peptide-pulsed and unpulsed lpr spleen cells were injected
into PKO mice 7 days postinfection. (B) LT359 peptide-pulsed and unpulsed
naive C57BL/6 spleen cells were injected into C57BL/6 or PKOmice during the
acute or persistent phase of the immune response. For both (A) and (B), values
represent mean±SEM percent specific lysis of peptide-pulsed spleen cells at 4 h
of 3 recipient mice in 2 separate experiments.
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late-appearing morbidity/mortality.
Discussion
The controversial concept that immunosurveillance protects
against spontaneously developing tumors has garnered strong
support from recent studies in humans and in mouse models
(Dunn et al., 2004). Perforin-mediated cytotoxicity is the
hallmark CD8 T cell effector mechanism in vitro (Kagi et al.,
1994; Walsh et al., 1994) and represents the dominant
pathway for CTL lysis in vivo (Barber et al., 2003; Byers et
al., 2003). Moreover, there is strong evidence documenting the
importance of perforin-mediated cytotoxicity in tumor rejec-
tion (van den Broek et al., 1996; Smyth et al., 1999; van Elsas
et al., 2001) and control of spontaneous malignancies (Smyth
et al., 2000). Thus, the central finding here that perforin-
deficient mice efficiently cleared infectious virus and were
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independent role for perforin/granzyme exocytosis in PyV
pathogenesis.
Perforin-deficient PyV-specific CD8 T cells appear to have
fully developed secretory lysosomal compartments because ex
vivo intracellular granzyme B staining and cognate peptide-
induced degranulation in PKOmice are comparable to wild type
C57BL/6 mice (Fig. 3A and data not shown). Although in vivo
cytotoxicity is largely perforin-dependent, a substantial amount
of antigen-specific killing is seen in PKO mice, suggesting that
a compensatory cytotoxicity pathway(s) enables CD8 T cells to
eliminate virally infected cells in the absence of perforin.
Decreased in vivo killing in the absence of both perforin and Fas
indicates that both of these effector pathways are operative in
the anti-PyV immune response (Fig. 4A). Because PKO:lpr
bone marrow chimeric mice are resistant to PyV-induced
tumors, however, CTL effector functions other than perforin-
and Fas/FasL-mediated cytolysis must confer tumor immuno-
surveillance. IFN-γ represents a candidate antitumor CD8 Tcell
effector mechanism. Rejection of transplanted tumors has been
shown to be markedly less effective in IFN-γ-deficient recipient
mice in situations where deficiencies in any of the three major
cytotoxic effector pathways (i.e., perforin-, Fas ligand- and
TNF-α-mediated cytotoxicity) have little effect (Dobrzanski et
al., 2004; Hollenbaugh et al., 2004). Alternatively, IFN-γ may
be required in concert with CD8 T cell cytotoxicity effector
activity to limit persistent PyV infection and confer protection
from PyV-induced tumors. By secreting cytokines and chemo-
kines, antigen-specific CD8 T cells may also indirectly mediate
antiviral and antitumor surveillance by recruiting and activating
other effector cells (e.g., macrophages, neutrophils).
The absence of in vivo antigen-specific cytotoxicity in
persistently infected PKO mice (Fig. 4B) suggests that Fas/FasL-
mediated cytotoxicity may predominantly operate during the acute
infection phase of the anti-PyV immune response. In contrast to the
TCR-dependent engagement of perforin/granzyme exocytosis,
cytokines are capable of upregulating surface expression of both
Fas on target cells and FasL on CD8 T cells (Esser et al., 1997).
The inflammatory cytokine-rich milieu during acute infection may
thereby superimpose FasL/Fas cytotoxicity on the perforin-
mediated pathway to most efficiently clear large-scale infection.
In contrast, lack of bystander Fas/FasL-mediated cytotoxicity
during the persistent phase of infection fits with the concept that
virus-specific CD8 T cells must balance control of persistent viral
replication against immunopathologic tissue damage.
We were unable to identify an immunomodulatory role for
perforin in the anti-PyV CD8 T cell response. The exaggerated
expansion of antigen-specific CD8 T cells during acute LCMVor
Listeria monocytogenes infection suggested that perforin down-
regulates CD8 T cell responses in concert with viral clearance
(Kagi et al., 1999; Matloubian et al., 1999). Subsequent studies,
however, showed that absence of perforin-mediated lysis of
epitope-expressing dendritic cells was associated with progressive
expansion in antigen-specific CD8 T cell numbers (Badovinac et
al., 2000, 2003; Yang et al., 2006), raising the question as to
whether persistent antigen drives uncontrolled CD8 T cell
expansion in PKO mice. Similar to our findings, Christensen etal. recently reported that PKO mice efficiently clear vesicular
stomatitis virus infection and mount virus-specific CD8 T cell
responses comparable to wild type mice (Christensen et al., 2004).
Thus, whether perforin modulates CD8 Tcell responses appears to
depend on the particular host–pathogen interaction being studied.
In summary, the findings described here demonstrate that
perforin is dispensable for limiting PyV infection or conferring
resistance to PyV-induced tumors. This study indicates that
other effector mechanisms, perhaps together with perforin/
granzyme exocytosis, are required to mediate surveillance for
infected/transformed cells in PyV-infected hosts.
Materials and methods
Mice
C3H/HeNCr and C57BL/6NCr mice were purchased from
the National Cancer Institute. B6.MRL-Tnfrsf6lpr, B6.129S-
Tnfrsf1atm1ImxTnfrsf1btm1Imx, C57BL/6-Pfptm1Sdz and C57BL/
6.β2m
−/− mice were purchased from The Jackson Laboratory
(Bar Harbor, ME). Mice were housed and bred in accordance
with the guidelines of the Institutional Animal Care and Use
Committee, and the Department of Animal Resources at Emory
University.
Virus and inoculations
PyV strain A2 was molecularly cloned, plaque purified and
virus stocks were prepared on baby mouse kidney cells, as
previously described (Lukacher and Wilson, 1998). Adult mice
(6–12 weeks of age) were inoculated subcutaneously in each
hind footpad with 1×106 PFU of virus. Newborn mice (<12 h
of birth) were inoculated subcutaneously in each hind footpad
with 2×105 PFU of virus.
In vivo CTL assay
This assay was performed as previously described (Byers
et al., 2003). Briefly, peptide-pulsed spleen cells were co-stained
with PKH26 and differential concentrations of CFSE and equal
numbers of peptide-pulsed and unpulsed cells were adoptively
transferred into infected or naive syngeneic recipients. At 4 h
after transfer, mice were sacrificed, organs harvested and single
cell suspensions of spleen were analyzed by flow cytometry.
Percent specific lysis of fluorescent donor spleen cells in each
mouse is calculated as follows: ((number of unpulsed targets×
A−number of peptide-pulsed targets) / number of unpulsed
targets×A) ×100, where A=(number of unpulsed targets /
number of peptide-pulsed targets) in uninfected recipient mice.
Plaque assay
Spleen samples were snap-frozen in sterile Kontes tubes
(Kontes, Vineland, NJ), adjusted to 50 mg/ml in DMEM at 4 °C
and homogenized using an overhead stirrer (Wheaton, Millville,
NJ) and disposable Teflon pestles (Kontes). Homogenized
tissues were then freeze–thawed three times, incubated for
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natants were titered for infectious virus by plaque assay on
BALB/3T3 clone A31 cells. The detection limit for this plaque
assay is 1 PFU/mg spleen.
Taqman real-time PCR
DNA was extracted from whole blood or snap-frozen
tissue using the QIAamp DNA Mini kit (Qiagen) according
to the manufacturer's instructions. Taqman PCR was
performed as described (Kemball et al., 2005). The PyV
DNA quantity is expressed in genome copies per milligram
of tissue and is calculated based on a standard curve of
known PyV genome copy number vs. threshold cycle of
detection. The detection limit with this assay is 10 copies of
genomic viral DNA.
Flow cytometry
RBC-lysed spleen cells were stained with allophycocyanin-
conjugated Db/LT359-LT638 (with the cysteine at position 7
replaced by α-aminobutyric acid, a thiol group-less cysteine
analog ) tetramers (prepared as described in Kemball et al.,
2006) and the following mAbs: FITC-conjugated anti-CD8α
(BDBiosciences) and PE-conjugated mAbs to CD27, CD122
and CD127 (eBioscience). For intracellular staining, spleen
cells were cultured for 4 h in 96-well round-bottom microtiter
plates in IMDM (Invitrogen) containing 10% FBS, penicillin/
streptomycin, 50 μM 2-ME, synthetic peptides and 1 μg/ml
brefeldin A (BFA). Cells were then stained for surface
markers, washed, permeabilized with Cytofix/Cytoperm (BD
Biosciences) and stained intracellularly using allophycocyanin-
conjugated anti-IFN-γ (XMG 1.2; BD Biosciences) or PE-
conjugated anti-TNF-α (MP6-XT22; Caltag). Staining for
granzyme B (GB12; Caltag) or its isotype control (mouse
IgG1) was carried out directly ex vivo on cells permeabilized
as above. Degranulation assays measuring surface expression
of CD107a and CD107b were carried out as described (Betts et
al., 2003). FITC-conjugated CD107a and CD107b were
purchased from BD Biosciences. Samples were acquired on
a FACSCalibur (BD Biosciences), and data were analyzed
using CellQuest (BD Biosciences) and FlowJo (TreeStar)
software.
Generation of radiation bone marrow chimeras
B6.MRL-Tnfrsf6lpr mice or wild type C57BL/6 mice were
lethally irradiated with 1000 rad and reconstituted 12 h later
with 2×107 bone marrow cells taken from the femurs of
C57BL/6-Pfptm1Sdz mice. Mice were rested for 10 weeks to
allow for hematopoietic cell reconstitution before s.c. infection
in hind footpads with 1×106 PFU of PyV. Complete
engraftment by PKO bone marrow was confirmed by PCR
using oligonucleotide primers and annealing conditions as
described (Bergmann et al., 2003). Assessment of PyV DNA
levels in blood and tissues of mice was performed at necropsy,
and mice were monitored for signs of tumor growth.Statistics
Statistical significance was determined by an unpaired
Student's t test, assuming unequal variances. A p value of
<0.05 was considered statistically significant.
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